Literature DB >> 3896284

Influence of nicardipine on blood pressure, renal function and plasma aldosterone in normotensive volunteers.

B A van Schaik, R J Hene, G G Geyskes.   

Abstract

The influence of the calcium antagonist nicardipine on intrarenal sodium handling and angiotensin II induced secretion of aldosterone was investigated in 18 normotensive volunteers after the first dose and after 1 week of treatment (20 mg three times daily). A short-lasting natriuresis was observed, which was caused by a decreased reabsorption of sodium localised in both proximal and distal tubules. Log plasma renin activity (PRA) fell significantly on each day during angiotensin II infusion, while log-plasma aldosterone (PA) rose significantly. The log PRA/log PA ratio was increased during nicardipine treatment. The secretion of aldosterone, induced by angiotensin II, was not influenced by nicardipine treatment. No effect of the drug on adrenal responsiveness to angiotensin II was found.

Entities:  

Mesh：

Substances：

Year:  1985        PMID： 3896284      PMCID： PMC1400768          DOI： 10.1111/j.1365-2125.1985.tb05148.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN： 0306-5251            Impact factor:   4.335


  20 in total

1.  The role of calcium in the stimulation of aldosterone production by adrenocorticotropin, angiotensin II, and potassium in isolated glomerulosa cells.

Authors:  J L Fakunding; R Chow; K J Catt
Journal:  Endocrinology       Date:  1979-08       Impact factor: 4.736

2.  Simultaneous single isotope radioenzymatic assay of plasma norepinephrine, epinephrine and dopamine.

Authors:  J D Peuler; G A Johnson
Journal:  Life Sci       Date:  1977-09-01       Impact factor: 5.037

Review 3.  Specific pharmacology of calcium in myocardium, cardiac pacemakers, and vascular smooth muscle.

Authors:  A Fleckenstein
Journal:  Annu Rev Pharmacol Toxicol       Date:  1977       Impact factor: 13.820

4.  Application of a radioimmunoassay for angiotensin I to the physiologic measurements of plasma renin activity in normal human subjects.

Authors:  E Haber; T Koerner; L B Page; B Kliman; A Purnode
Journal:  J Clin Endocrinol Metab       Date:  1969-10       Impact factor: 5.958

5.  Antihypertensive effect of fractionated sublingual administration of nifedipine in moderate essential hypertension.

Authors:  M Thibonnier; F Bonnet; P Corvol
Journal:  Eur J Clin Pharmacol       Date:  1980       Impact factor: 2.953

6.  Treatment of hypertension with nifedipine, a calcium antagonistic agent.

Authors:  M T Olivari; C Bartorelli; A Polese; C Fiorentini; P Moruzzi; M D Guazzi
Journal:  Circulation       Date:  1979-05       Impact factor: 29.690

7.  Calcium: its role in the mechanism of action of angiotensin II and potassium in aldosterone production.

Authors:  R Foster; M V Lobo; H Rasmussen; E T Marusic
Journal:  Endocrinology       Date:  1981-12       Impact factor: 4.736

8.  Antihypertensive and renal effects of nicardipine.

Authors:  B A van Schaik; A E van Nistelrooy; G G Geyskes
Journal:  Br J Clin Pharmacol       Date:  1984-07       Impact factor: 4.335

9.  Calcium antagonists decrease adrenal and vascular responsiveness to angiotensin II in normal man.

Authors:  J A Millar; K McLean; J L Reid
Journal:  Clin Sci (Lond)       Date:  1981-12       Impact factor: 6.124

10.  Antihypertensive and hormonal effects of single oral doses of captopril and nifedipine in essential hypertension.

Authors:  M E Soto; M Thibonnier; O Sire; J Menard; P Corvol; P Milliez
Journal:  Eur J Clin Pharmacol       Date:  1981       Impact factor: 2.953
View more
  4 in total

Review 1.  'Second generation' dihydropyridine calcium antagonists. Greater vascular selectivity and some unique applications.

Authors:  D D Freedman; D D Waters
Journal:  Drugs       Date:  1987-11       Impact factor: 9.546

2.  Aims of combination therapy--improved quality of life or better blood pressure control?

Authors:  D Maclean
Journal:  Drugs       Date:  1988       Impact factor: 9.546

Review 3.  Nicardipine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy, in the treatment of angina pectoris, hypertension and related cardiovascular disorders.

Authors:  E M Sorkin; S P Clissold
Journal:  Drugs       Date:  1987-04       Impact factor: 9.546

Review 4.  Do calcium channel blockers have renal protective effects?

Authors:  G P Reams
Journal:  Drugs Aging       Date:  1994-10       Impact factor: 3.923
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.